Sanofi aims for acne vaccine in new pact

Lured by the $3 billion acne treatment market, Sanofi Pasteur has inked a collaboration deal with with the University of California, San Diego to develop an immunological approach to fighting the skin condition.

Current treatments for acne use benzoyl peroxide and oral or topical antibiotics, which the company notes can disrupt the skin's balance and lead to more resistant forms of the bacteria. The collaboration will attempt to develop a vaccine that will neutralize Propionibacterium acnes factors in inflammation. Financial details of the two-year agreement weren't disclosed.

"This opportunity could provide an immunotherapeutic product with significant benefits and a novel mechanism of action to address an unmet medical need," noted Dr. Elias Zerhouni, president of Global R&D, in a release. "This investigational vaccine and treatment may lead to a better solution for the many who suffer from this skin disease."

- here's the Sanofi release

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Since the Warp Speed selections went public, experts have been wondering why some drugmakers were left off.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.